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ABSTRACT
Mesenchymal stem cells (MSCs) are found in a variety of tissues, including human bone marrow; secrete
hematopoietic cytokines; support hematopoietic progenitors in vitro; and possess potent immunosuppressive
properties. We hypothesized that cotransplantation of culture-expanded MSCs and hematopoietic stem cells
(HSCs) from HLA-identical sibling donors after myeloablative therapy could facilitate engraftment and lessen
graft-versus-host disease (GVHD); however, the safety and feasibility of this approach needed to be estab-
lished. In an open-label, multicenter trial, we coadministered culture-expanded MSCs with HLA-identical
sibling-matched HSCs in hematologic malignancy patients. Patients received either bone marrow or peripheral
blood stem cells as the HSC source. Patients received 1 of 4 study-specified transplant conditioning regimens
and methotrexate (days 1, 3, and 6) and cyclosporine as GVHD prophylaxis. On day 0, patients were given
culture-expanded MSCs intravenously (1.0-5.0  106/kg) 4 hours before infusion of either bone marrow or
peripheral blood stem cells. Forty-six patients (median age, 44.5 years; range, 19-61 years) received MSCs and
HLA-matched sibling allografts. MSC infusions were well tolerated, without any infusion-related adverse
events. The median times to neutrophil (absolute neutrophil count >0.500  109/L) and platelet (platelet
count >20  109/L) engraftment were 14.0 days (range, 11.0-26.0 days) and 20 days (range, 15.0-36.0 days),
respectively. Grade II to IV acute GVHD was observed in 13 (28%) of 46 patients. Chronic GVHD was
observed in 22 (61%) of 36 patients who survived at least 90 days; it was extensive in 8 patients. Eleven patients
(24%) experienced relapse at a median time to progression of 213.5 days (range, 14-688 days). The probability
of patients attaining disease- or progression-free survival at 2 years after MSC infusion was 53%. Cotrans-
plantation of HLA-identical sibling culture-expanded MSCs with an HLA-identical sibling HSC transplant is
feasible and seems to be safe, without immediate infusional or late MSC-associated toxicities. The optimal
MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation
should be evaluated further in phase II clinical trials.
© 2005 American Society for Blood and Marrow Transplantation
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3NTRODUCTION
Although allogeneic hematopoietic stem cell
HSC) transplantation is an effective therapeutic
odality for a variety of malignant and nonmalig-
ant disorders, it remains complicated by treat-
ent-related mortality because of infection and
leeding, regimen-related toxicity, engraftment fail-
re, and acute and chronic graft-versus-host disease
GVHD). [1,2] Even when HLA-identical siblings
re the source of HSCs for infusion, the likelihood
f developing clinically signiﬁcant acute and
hronic GVHD approaches 35% and 50%, respec-
ively. Investigators at Case Western Reserve Uni-
ersity described a homogeneous population of ad-
erent cells, termed mesenchymal stem cells (MSCs),
hat possess extensive proliferative capacity and the
bility to differentiate into mesenchymal lineages.
3] These cells were shown to secrete a variety of
olony-stimulating factors and cytokines, either
onstitutively or after stimulation, and could sup-
ort long-term culture-initiating cells and enhance
ngraftment in a preclinical model. [4-7] Further-
ore, these cells expressed class I, but not class II,
istocompatibility antigens and were not immuno-
enic in in vitro assays or in preclinical models.
8-10] MSCs also have been shown to suppress
rimary and ongoing mixed lymphocyte reactions
nd to delay skin graft rejection across major histo-
ompatibility barriers. [8-11]
A number of studies have shown that chemo-
herapy, radiation therapy, or their combination
amages the bone marrow (BM) microenvironment
nd may result in diminished or delayed hemato-
oiesis. [12-15] The damaged marrow stroma must
econstitute itself to provide the optimal environ-
ent for hematopoietic regeneration. Additionally,
xtremely limited numbers of donor MSCs are
ransferred during an allograft procedure, and, in
ost reports, recipients of conventional allogeneic
ransplants seem to have only host-type marrow
tromal cells after transplantation. [16-20] Lazarus
t al. [21] and Koç et al. [22] previously demon-
trated that autologous MSCs could be collected
rom cancer patients, undergo culture expansion ex
ivo, and then later be infused without toxicity. [21,22]
e report herein the results of our HLA-identical
ibling HSC myeloablative transplant clinical trial
esigned primarily to examine the safety and feasi-
ility of the cotransplantation of culture-expanded
onor-derived MSCs and donor HSCs in hemato-
ogic malignancy patients. Our secondary goals
ere to investigate the rates and kinetics of hema-
opoietic engraftment and incidence and the sever-
ty of GVHD. h
90ATIENTS AND METHODS
atients and Study Design
Between December 1999 and March 2001, 56
ematologic malignancy patients were enrolled. Par-
icipating institutions included the Comprehensive
ancer Center of Case Western Reserve University,
niversity Hospitals of Cleveland, Cleveland, OH;
niversity of Illinois-Chicago, Chicago, IL; Oregon
ealth and Science University, Portland, OR; Blood
Marrow Transplant Group of Georgia, Atlanta,
A; University of Colorado Health Sciences Center,
enver, CO; Roswell Park Cancer Institute, Buffalo,
Y; and Ospedale San Martino University, Genova,
taly. The clinical protocol and consent form were
pproved by the institutional review board for human
nvestigation at each participating center. Patients
ere required to have responsive or nonprogressive
isease, an Eastern Cooperative Oncology Group per-
ormance status of 0 or 1, and adequate visceral organ
unction (including a left ventricular ejection fraction
f at least 50%, forced expiratory volume in 1 second
nd diffusion of carbon monoxide greater than 50% of
redicted, serum direct bilirubin less than 2.0 mg/dL,
nd an actual or calculated creatinine clearance greater
han 60 mL/min). Patients were excluded for major
entral nervous system dysfunction or active infection.
x Vivo MSC Culture and Cryopreservation
After patient and donor enrollment, at least 30 mL
f BM aspirate was obtained under sterile conditions
y puncture of the posterior iliac crests of normal
LA-identical sibling donors. Aspirates were trans-
orted to the class 10 000 production suite of Osiris
herapeutics, Inc. (Baltimore, MD), and expansion of
SC culture was performed by using a modiﬁcation
f previously published methods. [22,23] Brieﬂy, the
spirate was mixed with 4 volumes of Dulbecco phos-
hate-buffered saline (DPBS; Gibco, Grand Island,
Y) in a sterile class II biologic safety cabinet and centri-
uged at 900 g for 10 minutes at 20°C in a Beckman
S-6R centrifuge (Palo Alta, CA). Pellets were lay-
red onto 25 mL of Percoll (density, 1.073 g/mL;
igma, St. Louis, MO) at a density of 1 to 2 107 cells
er milliliter. Samples were centrifuged at 900g for 30
inutes at 20°C, and recovered mononuclear cells
ere resuspended in DPBS and centrifuged at 460 g
or 10 minutes at 20°C. Cells were resuspended at 1
06 nucleated cells per milliliter in Dulbecco modiﬁed
agle medium, low glucose (Gibco), with selected
0% fetal bovine serum (Hyclone, Logan, UT); 30 mL
f the suspension was plated per 175-cm2 ﬂask (Falcon,
ranklin Lakes, NJ). The serum lot used was selected
n the basis of optimal MSC growth with maximal
etention of osteogenic differentiation as assessed with
n vitro and in vivo assays. [24] MSCs were cultured in
umidiﬁed incubators with 5% CO2 and initially al-
l
c
a
d
r
s
i
t
w
a
M
ﬂ
M
R
R
c
U
u
M
v
F
p
(
m
w
a
1
w
(
m
B
c
w
S
F
l
(
f
u
C
2
H
H
t
t
s
t
e
t
w
t
d
t
s
k
1
w
o
w
u
w
s
c
o
t
p
p
t
c
M
1
B
p
w
a
w
c
c
M
s
t
r
1
s
t
s
3
3
i
t
P
c
d
o
a
H
c
t
m
t
t
Cotransplantation of MSCs and HSCs
Bowed to adhere for 72 hours, followed by media
hange every 3 to 4 days. When cultures reached
pproximately 90% conﬂuence, adherent cells were
etached with 0.05% trypsin/ethylenediamine tet-
aacetic acid (Gibco) and replated (passaged) at a den-
ity of 1  106 per 175-cm2 ﬂask until processing for
nfusion. Cell cultures were assayed for MSC pheno-
ype (see below) and tested for sterility weekly. They
ere tested for the presence of endotoxin by limulus
mebocyte lysate (Associates of Cape Cod, Falmouth,
A) and for the presence of mycoplasma by DNA/
uorochrome staining (Bionique, Saranc Lake, NY).
SCs were cryopreserved in Plasmalyte (Baxter,
ound Hill, IL), 5% human serum albumin (Baxter,
ound Hill, IL), and 10% dimethyl sulfoxide (ﬁnal
oncentrations) (Research Industries, Salt Lake City,
T) in Cryocyte freezing bags (Baxter, Deerﬁeld, IL) by
sing a controlled-rate liquid nitrogen freezer. Total
SC cell counts were determined before cryopreser-
ation.
low Cytometry
To verify MSC character and homogeneity, the
urity (surface expression) of CD105 (SH-2), CD73
SH-3 and SH-4), CD14, and CD45 was deter-
ined on culture-expanded MSCs. Cells detached
ith trypsin were washed with DPBS plus 2% bovine
lbumin, ﬁxed with 1% paraformaldehyde, blocked in
0% normal goat serum, and incubated separately
ith primary SH-2, SH-3, and SH-4 antibodies
Osiris) followed by phycoerythrin-conjugated anti-
ouse immunoglobulin G (HL) antibody (Caltag,
urlingame, CA) or with ﬂuorescein isothiocyanate–
onjugated CD45 and phycoerythrin-labeled CD14
ith appropriate isotype controls (Becton Dickinson,
an Jose, CA). Flow cytometry was performed on a
ACScan (Becton Dickinson) equipped with an argon
aser, and data were analyzed with CellQuest software
Becton Dickinson). We adhered to the same criteria
or MSC infusion as in previous studies: ie, cell pop-
lations that did not meet 99% purity (CD105,
D73, CD14, and CD45) were discarded. [21-
3]
igh-Dose Chemotherapy and Allogeneic
SC Infusion
Blood samples of patients and donors were ob-
ained for HLA-A, -B, -C, -DR, and -DQ antigen
yping, and HLA-DRB1 alleles were assessed by using
equence-speciﬁc oligonucleotide probes. [25,26] At
he start of the study, each institution elected to use
ither BM or peripheral blood stem cells (PBSCs) as
he source of cellular rescue. Donor allogeneic HSCs
ere obtained by using either a standard BM harvest
echnique or a PBSC apheresis procedure with stan-
ard pheresis equipment after subcutaneous adminis- a
B&MTration of recombinant human granulocyte colony-
timulating factor (Amgen, Thousand Oaks, CA) 10 g/
g/d for 5 days. For BM harvest, a minimum of 2 
08 mononuclear cells per kilogram of recipient
eight was required; for PBSC collection, a minimum
f 2  106 CD34 cells per kilogram of recipient
eight was required. PBSCs were cryopreserved by
sing a controlled-rate liquid nitrogen freezer,
hereas BM harvest cells were usually not cryopre-
erved. Total PBSC counts were determined before
ryopreservation. Conditioning procedures included 1
f 4 regimens: (1) busulfan and cyclophosphamide, (2)
hiotepa and cyclophosphamide, (3) carmustine, eto-
oside, cytarabine, and melphalan, or (4) cyclophos-
hamide and total body irradiation. [27-32] BM and
hawed PBSCs were infused intravenously through a
entral venous catheter on day 0.
SC Infusion
The planned MSC dose-escalation scheme was
.0, 2.5, or 5.0  106/kg in both the patients receiving
M and those receiving PBSCs (a total of 18 evaluable
atients in each MSC dose group). Dose escalation
ithin an arm was not to occur until at least 6 evalu-
ble patients had reached 28 days after transplantation
ith no evidence of graft failure. Because of the time
onstraints required by patient transplantation proto-
ols, there were some difﬁculties in growing sufﬁcient
SCs in time for patient infusion for the group as-
igned to receive the 5.0  106/kg dose; only 5 pa-
ient/donor pairs were able to achieve this dose. As a
esult, the upper MSC dose in the study became 2.5
06 MSCs per kilogram. Before planned MSC infu-
ion, cells were shipped in liquid nitrogen containers
o the respective transplantation center. Cryopre-
erved MSC units were thawed at the bedside in a
7°C sterile water bath and infused intravenously over
0 minutes as described previously. [22] BM or PBSC
nfusions were performed 4 hours after the comple-
ion of MSC infusion.
rophylaxis and Treatment of GVHD
GVHD prophylaxis consisted of intravenous cy-
losporine 3 mg/kg/d in divided doses beginning the
ay before transplantation (day 1) and continued
nward. Methotrexate was administered intravenously
t a dose of 10 mg/m2 only on days 1, 3, and 6 after
SC transplantation. Patients were advanced to oral
yclosporine as tolerated. In the absence of GVHD,
he oral cyclosporine dose was reduced by approxi-
ately 5% weekly, beginning on or near day 100, and
herapy was usually discontinued by 6 months after
ransplantation. Acute and chronic GVHD were treated
ccording to institutional practices.
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3ngraftment, Toxicity Grading, GVHD Grading,
nd Tumor Assessment
All calculations were assessed from the day of
SC and MSC infusions (designated day 0). Neutro-
hil engraftment was deﬁned as the ﬁrst of 3 consec-
tive days of neutrophil count greater than 0.500 
09/L, and platelet engraftment was deﬁned as the
rst of 7 consecutive days on which the platelet count
xceeded 20  109/L without transfusion support.
oxic effects were graded by using the National Can-
er Institute Common Toxicity Criteria (version 2.0).
cute GVHD (onset within 100 days of transplanta-
ion) was graded 0 to IV (grade II to IV was consid-
red moderate to severe) by using a modiﬁcation of
he Glucksberg criteria. [33] Patients who survived
ore than 21 days after transplantation with evidence
f engraftment were considered at risk for acute
VHD. Chronic GVHD was graded as limited or
xtensive according to previously published criteria in
atients who survived more than 90 days with evi-
ence of engraftment. [34,35] Patients underwent re-
taging with external imaging techniques and diagnos-
ic marrow examinations as appropriate for each
alignancy every 3 months after HSC infusion. Stud-
es were not performed speciﬁcally to detect ectopic
one and cartilage formation. Relapse was deﬁned as
he recurrence of disease. Death in the absence of
ersistent relapse was categorized as nonrelapse mor-
ality.
upportive Care
All patients had multilumen indwelling central ve-
ous catheters and were cared for in single rooms.
ntibiotics were administered empirically for fever
nd neutropenia according to institutional guidelines,
nd all patients were supported with irradiated blood
omponents in an attempt to maintain the hematocrit
reater than 25% and the platelet count greater than
0  109/L or to treat bleeding complications due to
hrombocytopenia. Recombinant hematopoietic growth
actors were not administered routinely. Supportive
are was given according to individual institutional
ractices and included the use of seronegative or leu-
ocyte-ﬁltered blood components in cytomegalovirus
CMV)–seronegative patients [36]; weekly intravenous
mmunoglobulin in CMV-seropositive patients for the
rst 100 days [37]; ganciclovir with or without intra-
enous immunoglobulin for CMV reactivation (diag-
osed with viral culture or polymerase chain reaction
PCR]) [38]; and Pneumocystis carinii pneumonia pro-
hylaxis with trimethoprim-sulfamethoxazole, dap-
one, or inhaled pentamidine (in sulfa-allergic pa-
ients) at the start of the transplantation conditioning
egimen (withheld until the neutrophil count ex-
eeded 0.500 109/L and resumed until immunosup-
ressive therapy was discontinued). Antifungal agent w
92rophylaxis with ﬂuconazole, amphotericin B, liposo-
al amphotericin, or other agents was administered
ccording to the practice at each institution.
nd Points
Primary and secondary outcomes were (1) deter-
ination of the short- and long-term safety of MSC
nfusions, (2) donor-derived engraftment, (3) nonre-
apse mortality, (4) overall survival, (5) disease-free
urvival (survival without recurrent malignancy after
ransplantation), (6) acute GVHD, and (7) chronic
VHD. Patients with recurrent tumors were cen-
ored at the time of relapse, and those alive in remis-
ion were censored at the last follow-up evaluation.
or disease-free survival, cases were considered treat-
ent failures at the time of relapse or death from any
ause; patients alive in continuous remission were cen-
ored at the last follow-up evaluation.
tatistical Analysis
Estimates of disease-free and overall survival were
btained by analysis of life-table methods according to
he Kaplan-Meier method: follow-up was censored at
he date of last contact among survivors. [39] Cumu-
ative incidence rates of grades II to IV and grades III
o IV acute GVHD, chronic GVHD, relapse/progres-
ion, and nonrelapse mortality were computed to al-
ow for competing risks. All outcomes were tested for
he assumption of potential hazards by using a time-
ependent covariate. All computations were made by
sing the procedure PHREG in the statistical package
AS version 8.0 for UNIX (SAS Institute, Cary, NC).
ssessment of MSC Chimerism
fter Transplantation
BM aspirates were collected from a subset of pa-
ients at approximately 6 and 18 months after trans-
lantation to assess the presence of donor chimerism
ithin the stromal cell compartment. Because of the
oor cellular growth of many BM specimens, as well
s sample storage issues, chimerism results were avail-
ble for only a small subset of patients at inconsistent
ime points. Heparinized BM aspirates were placed in
SC culture as described previously and were allowed
o reach conﬂuence in primary culture over 1 to 2
eeks. MSCs from primary cultures then were har-
ested after trypsinization and sent to the University
f Illinois Molecular Diagnostics Laboratory for anal-
sis after cryopreservation. Genomic DNA was iso-
ated by using the Puregene DNA Isolation Kit (Gen-
ra Systems, Inc., Minneapolis, MN). A panel of 9
icrosatellite loci and a segment of the X-Y homol-
gous gene amelogenin were ampliﬁed by multiplex
CR. PCR primer pairs speciﬁc for each microsatel-
ite and the amelogenin segment were synthesized
ith the forward primer containing a 5= end–labeled
ﬂ
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Cotransplantation of MSCs and HSCs
Buorophore to allow for automated ﬂuorescence de-
ection. Each PCR reaction contained 5 ng of
enomic DNA and 2.5 U of Amplitaq Gold Polymer-
se (Perkin Elmer, Foster City, CA). After 45 cycles of
mpliﬁcation in a Perkin Elmer 9600 thermal cycler,
CR products were combined with the GeneScan-350
nternal lane size standard (Perkin Elmer) labeled with
AMRA. Two microliters of each PCR product was
lectrophoresed through a 4% polyacrylamide dena-
uring gel by using an ABI 377 DNA Sequencer (ABI
rism; Applied Biosystems, Foster City, CA). PCR-
mpliﬁed microsatellite alleles were detected by Ge-
escan Analysis software (Applied Biosystems) during
lectrophoresis. The automated ﬂuorescence detec-
ion assay can detect 1% to 99% mixtures of donor
nd recipient cells.
ESULTS
atient Disposition
A total of 56 patients successfully underwent
creening and provided written informed consent. Ex-
ansion of MSCs up to 2.5 106 cells per kilogram of
ecipient weight from an aliquot of donor BM was
easible in 51 (91%) of 56 donors. Forty-six patients
eceived MSC infusions (19 in the BM group and 27
n the PBSC group). Of these 46, 30 patients com-
leted the study through the 1-year follow-up study
valuation (n  13 in the BM group and n  17 in the
BSC group), and 25 patients completed the study
hrough the 2-year follow-up study evaluation (n  9
n the BM group and n 16 in the PBSC group). The
edian BM volume aspirated for MSC culture was
4.5 mL (range, 32.0-74.5 mL). The median time to
row the planned dose of MSCs in ex vivo culture was
1 days (range, 21-48 days). The time to achieve an
SC dose of 1.0 versus 2.5  106/kg did not differ
igniﬁcantly: 30 days (21-47 days) versus 32 days
22-48 days), respectively (P  .298; t test). The rea-
ons for failure of enrolled patients to proceed to
SC therapy were failure to obtain or expand ade-
uate numbers of MSCs or failure to mobilize ade-
uate numbers of HSCs (n  5); ineligibility because
f the development of an intercurrent illness (n  2);
nd patient withdrawal or refusal of treatment before
he infusion of cells (n  1). One donor and 2 patients
ere deemed ineligible upon review of screening as-
essments.
emographic Information and Definitions
Baseline patient characteristics are summarized in
able 1. A total of 46 patients received MSC infu-
ions. The median patient age was 44.5 years (range,
9 to 61 years), and there were 22 women and 24 men.
hree-quarters of the patients (n  34) were CMV p
B&MTeropositive, and chronic myeloid leukemia was the
ost common diagnosis (n  14).
linical Response: Engraftment
The median hematopoietic cell doses infused were
.6  108 mononuclear cells per kilogram of recipient
eight (range, 2.1-5.5  108/kg) for BM transplants
nd 5.0  106 CD34 cells per kilogram of recipient
eight (range, 3.2-15.8  106/kg) for PBSC trans-
lants. Data for the 42 patients who survived at least
0 days after transplantation and were evaluable for
ngraftment are summarized in Table 2. Overall, the
edian time to achieve neutrophil engraftment (ab-
olute neutrophil count 0.500  109/L and 1.0 
09/L) was 14.0 days (range, 11.0-26.0 days) and 15.0
ays (range, 12.0-24.0 days), respectively. Subjects
ho received BM grafts had a slower absolute neutro-
hil count recovery 0.500  109/L compared with
BSC recipients: median 15.5 days (range, 11.0-26.0
ays) versus 13.5 days (range, 11.0-21.0 days), respec-
ively. Overall, the median time to achieve platelet
ngraftment 20  109/L and 50  109/L was 20.5
ays (range, 15.0-36.0 days) and 21.0 days (range,
5.0-36.0 days), respectively. The use of PBSCs versus
M and the MSC dose did not inﬂuence the time to
able 1. Patient Demographic Summary (n  46)
Characteristic Data
ge (y)
Median 44.5
Range 19-61
ex
Male 24 (52%)
Female 22 (48%)
MV-positive donor 24 (52%)
MV-positive patient 34 (74%)
alignancy/No. CR1/CP CR2/AP Rel/Ref/BC
ML/5 3 1 1
LL/7 4 3 —
LL/2 — — 2
ML/14 10 2 2
M/2 — — 2
HL/10 1 — 9
DS/5 — — 5
ther/1 — — 1
Total/46
ML indicates acute myeloid leukemia; ALL, acute lymphoblastic
leukemia; CLL, chronic lymphocytic leukemia; CML, chronic
myeloid leukemia; MM, multiple myeloma; NHL, non-
Hodgkin lymphoma; MDS, myelodysplastic syndrome; CR1,
ﬁrst complete remission; CR2, second complete remission; Rel/
Ref, relapsed or refractory disease; CP, chronic phase (CML
only); AP, accelerated phase (CML only); BC, blast crisis (CML
only).latelet recovery.
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3raft-versus-Host Disease
Table 3 indicates the incidence and severity of
VHD. Overall, 23 (50%) of 46 patients experienced
cute GVHD, which was at least grade II in 13 (28%)
f 46 subjects. The overall incidence of any grade
cute GVHD was 74% (14/19) in the BM group,
ompared with 33% (9/27) in the PBSC group. Fur-
her, only 5 patients (11%) developed grade III and 2
4%) patients developed grade IV acute GVHD.
wenty-two (61%) of 36 evaluable patients who sur-
ived at least 90 days after transplantation experienced
hronic GVHD that was limited in 14 and extensive in
; 12 BM recipients, compared with 10 PBSC recipi-
nts, developed chronic GVHD.
elapse
Twelve patients experienced tumor relapse or pro-
ression at a median of 213.5 days (range, 14-688
ays). The proportion of affected subjects was higher
n the BM group (6/19; 32%) than in the PBSC group
6/27; 22%). Given the small sample sizes, differences
n relapse/progression were not apparent between
oses of MSCs.
able 2. Time to Engraftment for All Patients (Marrow and Peripher
Variable
1.0  106/kg
(n  18)
ays to ANC >0.500  109/L
No. evaluable 18
Median 14.0
Range 12.0-26.0
ays to ANC >1.000  109/L
No. evaluable 17
Median 15.0
Range 12.0-23.0
ays to platelets >20  109/L
No. evaluable 12
Median 21.0
Range 16.0-34.0
ays to platelets >50  109/L
No. evaluable 12
Median 21.5
Range 18.0-34.0
NC indicates absolute neutrophil count.
able 3. Summary of GVHD for All Patients by Stem Cell Source and
Variable
BM vs. PBSCs
BM
(n  19)
PBSCs
(n  27)
cute GVHD 14 9
cute GVHD > grade II 5 8
imited chronic GVHD 8 6
xtensive chronic GVHD 4 4
M indicates bone marrow; PBSCs, peripheral blood stem cells; M
ata are number of patients.
94urvival
The probability of 2-year disease-/progression-
ree and overall survival for all patients was 53% (95%
onﬁdence interval, 37%-66%) and 78% (95% conﬁ-
ence interval, 63%-87%), respectively. Ten patients
ied, 2 each as a result of infection, relapse, and
emorrhage and 1 each as a result of hepatic veno-
cclusive disease, GVHD, and cardiac and gastroin-
estinal dysfunction. Three deaths occurred in the BM
roup (3/19; 16%), and 7 occurred in the PBSC group
7/27; 26%).
linical Safety Outcomes
As anticipated for HSC transplant recipients given
yeloablative therapy, all 46 patients experienced at
east 1 adverse event during the study period, and 39
85%) of 46 developed at least 1 grade 4 adverse event
Table 4). Only 7 patients (15%) demonstrated ad-
erse events that were considered treatment related,
uch as GVHD, organ failure, or others (ie, possibly,
robably, or deﬁnitely); this cluster included 1 patient
5%) in the BM group and 6 patients (22%) in the
BSC set. No patient, however, experienced infu-
HSCs)
MSC Dose
Total
(n  42)
2.5  106/kg
(n  19)
5.0  106/kg
(n  5)
19 5 42
13.0 15.0 14.0
11.0-21.0 11.0-22.0 11.0-26.0
19 5 41
14.0 19.0 15.0
12.0-21.0 12.0-24.0 12.0-24.0
14 4 30
21.5 16.0 20.5
16.0-36.0 15.0-17.0 15.0-36.0
14 4 30
21.5 17.0 21.0
16.0-36.0 15.0-18.0 15.0-36.0
Dose
MSC Dose Groups (BM  PBSCs)
All Patients
(N  46)
06/kg
20)
2.5  106/kg
(n  21)
5.0  106/kg
(n  5)
8 3 23
6 1 13
4 2 14
5 0 8
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Cotransplantation of MSCs and HSCs
Bional toxicity during the MSC infusion, nor were any
ubjects noted to have evidence of ectopic bone or
artilage formation on external imaging studies when
hese were performed for clinical care, such as tumor
estaging or management of infection.
etection of MSC Chimerism
fter Transplantation
Eighteen patients at a median of 8 months (range,
-13.5 months) after transplantation underwent BM
spiration to assess the presence of donor chimerism
n the stromal cell compartment. In 16 of 18 subjects,
o donor-derived MSCs were detected in posttrans-
lantation MSC cultures by using informative micro-
atellites (limit of detection, 1%). In 2 patients, 2% to
4% of the MSCs obtained from BM culture were of
onor origin. An additional 7 patients underwent a
econd BM aspiration at a median of 16 months
range, 10-18 months). In 2 subjects (the same ones
ho had donor-derived MSCs detected in the earlier
ampling), 6% to 11% of MSCs obtained from BM
ulture were donor derived. The remaining 5 patients
nalyzed had no evidence of donor-derived MSC en-
raftment.
ISCUSSION
In this study involving a heterogeneous population
f hematologic malignancy patients, we demonstrated
hat cotransplantation of HLA-identical sibling cul-
ure-expanded MSCs given in the course of an HLA-
dentical HSC transplantation after myeloablative
onditioning is safe. Additionally, it is feasible to pro-
ide a homogeneous population of donor MSCs at a
ose of 2.5  106 cells per kilogram without resulting
able 4. Summary of Adverse and Severe Adverse Events for All Patie
Variable
1.0  106/kg
(n  20)
1 adverse event 20
1 severe adverse event 14
atal severe adverse events 5
ighest NCI grade or severity
Grade 1 1
Grade 2 2
Grade 3 1
Grade 4 16
elationship*
Not related 18
Related 2
t each level of summation (except for the row for 1 adverse eve
ata are number of patients.
CI indicates National Cancer Institute.
Not related indicates unrelated or unlikely relationship; related inn a delay in performing the transplantation; sufﬁcient c
B&MTSCs were available for infusion from 51 (91%) of 56
onors. In 5 donor/recipient pairs, however, we were
nable to expand MSCs ex vivo in a timely fashion.
he worry of tumor progression while attempting to
ollect the target dose of MSCs as well as adequate
umbers of HSCs necessitated removing patients
rom the study. Furthermore, no adverse MSC infu-
ion–related events occurred with the administration
f donor MSCs into the 46 patients who completed a
yeloablative preparative regimen. Additionally, we
id not detect evidence of ectopic bone or cartilage
ormation by using external imaging studies when
hese were performed for clinical care, such as tumor
estaging or management of infection.
Hematopoietic recovery was prompt for most
atients. The median time to neutrophil recovery
0.500  109/L and platelets 20  109/L (untrans-
used) for all patients was 14 days (range, 11-26 days)
nd 20.5 days (range, 15-36 days), respectively. All
atients received the GVHD prophylaxis regimen of
yclosporine and methotrexate therapy on days 1, 3,
nd 6. Neutrophil recovery was faster in patients given
obilized PBSCs rather than BM as the stem cell
ource. This ﬁnding could be anticipated, because a
umber of trials have demonstrated that the use of
BSCs rather than BM is usually associated with a
ore rapid recovery of neutrophil and platelet counts.
ne explanation for this result is infusion of more
D34 cells with mobilized PBSCs as the stem cell
ource. [40-49] MSCs produce cytokines that are sup-
ortive of hematopoiesis and that therefore could po-
entially enhance marrow recovery, although the use
f exogenous hematopoietic growth factors was per-
itted, thus further clouding the effect of MSC infu-
ion on engraftment. [50,51] A randomized phase III
us MSC Dose
C Dose Groups
BM  PBSCs)
Total
(N  46)
2.5  106/kg
(n  21)
5.0  106/kg
(n  5)
21 5 46
16 2 32
5 1 11
0 1 2
0 0 2
1 1 3
20 3 39
17 4 39
4 1 7
ients reporting more than 1 event were counted only once.
a possible, probable, or deﬁnite relationship.nts vers
MS
(
nt), patlinical trial using uniformity in the preparative regi-
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3en and stem cell donor source will be necessary to
ocument whether MSC infusion enhances the time
o neutrophil and platelet count recovery in the course
f an allogeneic transplantation.
In this trial, we intended for GVHD prophylaxis
o consist of cyclosporine and methotrexate, the latter
o be given only on days 1, 3, and 6 after transplan-
ation because of theoretical concerns about damaging
he recently infused MSCs. We did not observe an
ncrease in severe acute GVHD despite omitting the
ay 11 methotrexate dose, as has been suggested.
52,53] In this study, acute GVHD did not develop in
3 of 46 MSC recipients. Furthermore, grade III/IV
cute GVHD occurred only in 7 (15%) of 46 patients.
ixty percent of our patients received PBSCs rather
M as an HSC source, and this is thought to be a risk
actor for increasing the incidence and severity of
VHD. In our series, chronic GVHD occurred in 22
atients (limited, n  14; extensive, n  8). Many
eports have addressed the incidence of acute and
hronic GVHD in sibling-matched allogeneic stem
ell transplantation patients. [40-49,54] Most of the
eries have small numbers of patients, and several are
ased on registry data. In the 2 largest prospective
tudies, however, the incidence for grade II to IV and
II/IV acute GVHD ranged from 44% to 64% and
rom 12% to 26%, respectively. [44,47] Reported ex-
ensive chronic GVHD rates in these 2 reports ranged
rom 30% to 46%. Acute and chronic GVHD rates
dentiﬁed in the trial patients receiving HLA-matched
SCs and HSC allografts fall within these ranges.
andomized trials will be required to establish the
eneﬁt of an approach that uses MSC infusions.
In vitro, MSCs seem to suppress T-cell prolifera-
ion both by cell/cell interaction and via soluble fac-
ors. [11,55-59] Le Blanc et al. [60] recently reported
arked clinical suppression of refractory GVHD in a
atient given haploidentical “third party” MSCs. These
ransplantable cells may be ideal to help regulate im-
une responses after an allogeneic HSC transplanta-
ion. [61] Conversely, suppressed T-cell function has
he potential to abrogate graft-versus-leukemia activ-
ty in the allograft setting. Several groups have dem-
nstrated that BM stromal cells may facilitate tumor
rowth in in vitro and preclinical models. In this
tudy, we did not observe an increased number of
atients developing tumor progression. [62,63] On the
asis of our data, we believe that cotransplantation of
ulture-expanded MSCs with an HLA-identical sib-
ing HSC transplant seems to be safe and feasible. The
ptimal MSC dose and frequency of administration to
revent or treat GVHD during allogeneic HSC trans-
lantation should be evaluated further in phase II
linical trials.
We were able to demonstrate stromal cell chimer-
sm in only 2 of 19 patients in whom marrow aspirates
ere obtained at 6 and 18 months after transplanta-
96ion. These data may reﬂect the fact that an aspirate
ather than a biopsy sample was used. Baboon transplant
ata indicate a low frequency (1:1000 to 1:10 000) of
SCs in biopsy samples, and perhaps MSCs cannot
e detected in aspirates by using currently available
echniques. [10] Future studies addressing this issue
hould involve the infusion of more MSCs and more
ensitive PCR assays.
The vast majority of patients were able to partic-
pate in this trial. Five subjects were unable to proceed
ecause MSCs could not be expanded sufﬁciently in
itro, in part because of time constraints. The median
ime required for expansion of MSCs was 31 days
range, 21-48 days), and this may have restricted re-
ipient participation because of the time-consuming
nd labor-intensive procurement of patient-speciﬁc
llogeneic MSCs. Additionally, MSC effects could be
ose dependent, an end point we were unable to assess
ecause of limitations in reaching our upper target of
 106 MSCs per kilogram before infusion. If the
SC dose required to achieve a durable therapeutic
ffect is much higher, then it may be necessary to use
lternative strategies. Investigators have demonstrated
hat MSCs do not express the immune costimulatory
olecules CD40, CD80, and CD86 (relatively non-
mmunogenic) [4,58]; the MSC immunomodulatory
ffect does not seem to be major histocompatibility
omplex restricted, because similar effects can also be
bserved with third-party donor cells. [10] Therefore,
ulture-expanded MSCs obtained from unrelated, ma-
or histocompatibility complex–unmatched, healthy,
hird-party donors—ie, a “universal donor product”—
ould be a readily available product that may provide
n opportunity for multiple and higher MSC doses,
otentially at a reduced cost. Future investigations to
ssess the efﬁcacy of MSC infusion in HSC transplan-
ation may be facilitated by pursuing such an ap-
roach.
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